102 related articles for article (PubMed ID: 33983530)
1. Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer.
Zhou X; Zhu X; Yao J; Wang X; Wang N
Invest New Drugs; 2021 Dec; 39(6):1469-1483. PubMed ID: 33983530
[TBL] [Abstract][Full Text] [Related]
2. Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.
Zhuang H; Chen X; Wang Y; Huang S; Chen B; Zhang C; Hou B
Cancer Immunol Immunother; 2022 Mar; 71(3):601-612. PubMed ID: 34279685
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive prognostic and immune analysis of a glycosylation related risk model in pancreatic cancer.
Liu X; Shi J; Tian L; Xiao B; Zhang K; Zhu Y; Zhang Y; Jiang K; Zhu Y; Yuan H
BMC Cancer; 2023 Dec; 23(1):1229. PubMed ID: 38097951
[TBL] [Abstract][Full Text] [Related]
4. High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer.
Zhang G; Shu Z; Yu J; Li J; Yi P; Wu B; Deng D; Yan S; Li Y; Ren D; Hou Y; Lan C
Front Immunol; 2024; 15():1341209. PubMed ID: 38352864
[TBL] [Abstract][Full Text] [Related]
5. Single-minded homolog 2 as a potential prognostic signature and assessment of its correlation with immune cell infiltration in pancreatic cancer.
Hu Q; Wen N; Li F; Yang D; Yue C; Wu Z; Li M; Lu H
Pol J Pathol; 2023; 74(4):232-247. PubMed ID: 38477085
[TBL] [Abstract][Full Text] [Related]
6. Identification of the Shared Gene Signatures and Biological Mechanism in Type 2 Diabetes and Pancreatic Cancer.
Hu Y; Zeng N; Ge Y; Wang D; Qin X; Zhang W; Jiang F; Liu Y
Front Endocrinol (Lausanne); 2022; 13():847760. PubMed ID: 35432196
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target.
Ren LK; Lu RS; Fei XB; Chen SJ; Liu P; Zhu CH; Wang X; Pan YZ
J Cancer Res Clin Oncol; 2024 Mar; 150(3):127. PubMed ID: 38483604
[TBL] [Abstract][Full Text] [Related]
8. FLNB overexpression promotes tumor progression and associates with immune suppression, evasion and stemness in pancreatic cancer.
Fan G; Yan Q; Chen Y; Han M; Wu Z; Ruan S; Zhuang H; Gou Q; Hou B
Am J Cancer Res; 2024; 14(2):709-726. PubMed ID: 38455418
[TBL] [Abstract][Full Text] [Related]
9. EPYC functions as a novel prognostic biomarker for pancreatic cancer.
Yang Z; Li H; Hao J; Mei H; Qiu M; Wang H; Gao M
Sci Rep; 2024 Jan; 14(1):719. PubMed ID: 38184732
[TBL] [Abstract][Full Text] [Related]
10. Association of ACP5 with the tumor immune microenvironment and its role in cell proliferation and metastasis in pancreatic cancer.
Shen J; Shi M; Song A; Ming Y; Zhu X; Ruan Y; Zhang T; Zhou G
Am J Transl Res; 2023; 15(11):6437-6450. PubMed ID: 38074824
[TBL] [Abstract][Full Text] [Related]
11. A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers.
Goonesekere NC; Wang X; Ludwig L; Guda C
PLoS One; 2014; 9(4):e93046. PubMed ID: 24740004
[TBL] [Abstract][Full Text] [Related]
12. Prognostic biomarker TPM4 acts as a potential predictor of PD-1/PD-L1 inhibitor response in glioblastoma.
Dai L; Touhid ME; Zhou P; Jiang S
Asian J Surg; 2024 Apr; ():. PubMed ID: 38653702
[No Abstract] [Full Text] [Related]
13. ncRNAs-mediated high expression of SEMA3F correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma.
Lou W; Wang W; Chen J; Wang S; Huang Y
Mol Ther Nucleic Acids; 2021 Jun; 24():845-855. PubMed ID: 34026328
[TBL] [Abstract][Full Text] [Related]
14. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.
Wang Q; Yu X; Zheng Z; Chen F; Yang N; Zhou Y
PeerJ; 2021; 9():e11342. PubMed ID: 33987018
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic, Therapeutic, and Prognostic Value of the Thrombospondin Family in Gastric Cancer.
Lu Y; Kong X; Zhong W; Hu M; Li C
Front Mol Biosci; 2021; 8():647095. PubMed ID: 33996903
[No Abstract] [Full Text] [Related]
16. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
Front Oncol; 2021; 11():607224. PubMed ID: 34026603
[TBL] [Abstract][Full Text] [Related]
17. Ferroptosis-Related Gene Signature Accurately Predicts Survival Outcomes in Patients With Clear-Cell Renal Cell Carcinoma.
Chang K; Yuan C; Liu X
Front Oncol; 2021; 11():649347. PubMed ID: 33996565
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value and Related Regulatory Networks of MRPL15 in Non-Small-Cell Lung Cancer.
Zeng Y; Shi Y; Xu L; Zeng Y; Cui X; Wang Y; Yang N; Zhou F; Zhou Y
Front Oncol; 2021; 11():656172. PubMed ID: 34026630
[TBL] [Abstract][Full Text] [Related]
19. VWCE as a potential biomarker associated with immune infiltrates in breast cancer.
Huo Q; Li Z; Chen S; Wang J; Li J; Xie N
Cancer Cell Int; 2021 May; 21(1):272. PubMed ID: 34020650
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of LIMK1 Is Correlated With Poor Prognosis and Immune Infiltrates in Lung Adenocarcinoma.
Lu G; Zhou Y; Zhang C; Zhang Y
Front Genet; 2021; 12():671585. PubMed ID: 34149814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
